Contalgin

Quick links to important sections

Contalgin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Contalgin

What is Contalgin?

Contalgin is a medicinal product used for the management of severe pain. It belongs to a group of medications known as opioids, which act on the central nervous system to relieve pain.

Composition and Form

The active substance in Contalgin is morphine sulfate. The medication is typically formulated as prolonged-release tablets. Unlike immediate-release medications, the prolonged-release mechanism allows for a gradual and steady release of the active ingredient into the bloodstream over an extended period. This design is intended to provide consistent pain relief and reduce the frequency of administration.

Mechanism of Action

Contalgin works by interacting with specific receptors in the brain and spinal cord. By binding to these receptors, the medication alters the way the body perceives and responds to pain signals. This process helps to alleviate intense or persistent pain that has not been adequately controlled by non-opioid analgesics.

General Use

This medication is primarily used for the treatment of chronic, severe pain conditions where long-term, continuous pain management is required. It is intended for individuals whose pain is severe enough to necessitate daily, around-the-clock opioid treatment.

What side effects are possible with Contalgin?

Possible Side Effects and Safety Information

This section describes the adverse effects and safety characteristics of Contalgin (Morphine Sulfate Extended-Release) as documented in official government regulatory documents.

Safety data categorizes adverse reactions based on their observed frequency. The most common adverse reactions listed include constipation, nausea, and sedation (somnolence). Other commonly reported effects include vomiting, headache, lightheadedness, dizziness, sweating, and pruritus (itching).

Adverse reactions are further categorized by the System-Organ-Class (SOC) they affect. Documented effects involve the Nervous System (e.g., sedation), Gastrointestinal System (e.g., constipation), Respiratory System (e.g., respiratory depression), and Vascular System (e.g., hypotension).

Serious Adverse Reactions

Official labels contain high-level warnings regarding several serious safety risks. These include life-threatening respiratory depression, which is the primary serious risk, particularly upon initiation of therapy or following a dose increase. Other critical safety warnings address the risk of Addiction, Abuse, and Misuse. Prolonged use during pregnancy can lead to Neonatal Opioid Withdrawal Syndrome (NOWS).

Population and Duration Safety Notes

The regulatory profile specifies safety considerations for certain groups. Elderly, cachectic, and debilitated patients are noted to have an increased risk for respiratory depression. Caution is also advised for patients with severely impaired renal or hepatic function. Furthermore, risks such as Adrenal Insufficiency are associated with long-term use of the medication.

Safety Constraints

Contalgin is subject to high-level safety restrictions. It is contraindicated in cases of significant respiratory depression, acute or severe bronchial asthma, and known or suspected paralytic ileus (gastrointestinal obstruction). The label also notes the risk of profound sedation, coma, and death when used concurrently with other Central Nervous System depressants.

Overdose and Emergency Response

Contalgin Overdose and When to Seek Help

Contalgin (morphine extended-release) overdose is a medical emergency that is consistently classified as a serious, life-threatening, or fatal risk by regulatory agencies. The most critical manifestation is respiratory depression—slowed, shallow, or stopped breathing—which can occur at any time, especially following dosage increases.

The classic triad of opioid overdose symptoms includes pinpoint pupils, unresponsiveness (coma), and respiratory depression. Other signs may include severe drowsiness, low blood pressure, and cold, clammy skin.

When to Seek Immediate Medical Help:

Call emergency services (e.g., 911) immediately if you observe any symptoms of severe respiratory problems or unresponsiveness. The risk is significantly increased by accidental ingestion (especially in children, where one dose can be fatal), improper use (crushing or chewing the tablet, which releases a potentially fatal dose), or concomitant use with Central Nervous System (CNS) depressants, including alcohol.

Immediate medical intervention is required for all suspected overdose situations, and healthcare professionals may administer the antidote naloxone. Patients exposed to extended-release opioids may require prolonged observation due to the drug's long duration of action.

Therapeutic Uses of Contalgin

What Contalgin Treats: Main Uses and Benefits

Contalgin is commonly used for managing severe, chronic pain that requires round-the-clock analgesia. This medication is applied in clinical situations where pain is persistent, high-intensity, and may be classified as intractable or severe. Contalgin is relevant in the therapeutic domains of cancer pain management, certain types of chronic non-malignant pain, and for symptom support in palliative care settings.


The therapeutic benefit may assist in maintaining stable pain levels continuously, contributing to the easing of relentless discomfort that severely interferes with a patient's quality of life. This medication may be part of symptomatic management to help ease the overall symptom burden during challenging symptomatic phases.


Quick Fact: Relief for Severe, Persistent Pain

This extended-release formulation assists with managing symptoms for patients needing around-the-clock support for well-being and daily functioning.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The use of Contalgin (Morphine Sulfate Extended-Release) is strictly governed by regulatory eligibility criteria, focusing on the patient's condition, age, and existing health status.

Contalgin is reserved for patients with severe pain requiring daily, around-the-clock, long-term opioid treatment for whom alternative treatments are inadequate or insufficient. Higher-strength doses are restricted to opioid-tolerant patients.

Contraindications

The medicine must not be used by patients with:

  • Significant respiratory depression or acute/severe bronchial asthma.
  • Known or suspected gastrointestinal obstruction, including paralytic ileus.
  • Known hypersensitivity to morphine or concurrent use of Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

Eligibility Restrictions

  • Pediatric Use: Safety and effectiveness have not been established in pediatric patients.
  • Geriatric Use: Caution is required for older adults, with close monitoring recommended due to increased risk.
  • Organ Function: Use requires caution in patients with severe renal or hepatic impairment.
  • Pregnancy/Lactation: Prolonged use during pregnancy may result in Neonatal Opioid Withdrawal Syndrome; use is not recommended while breastfeeding.

What should I know about interactions with other medicines?

Interaction scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions: Central Nervous System (CNS) Depressants; Monoamine Oxidase Inhibitors (MAOIs); Serotonergic drugs; Mixed Agonist/Antagonist Opioids; P-glycoprotein (P-gp) Inhibitors/Inducers; Oral P2Y12 Inhibitors.
Specific interacting medicines (if explicitly listed): Cimetidine; Rifampicin; Pentazocine; Nalbuphine; Butorphanol.
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic Reinforcement (Additive CNS depression); Pharmacokinetic (Inhibition of metabolism; P-gp Substrate effect); Administration-timing effect (Alcohol-related release disruption).
Timing-based interaction rules (if applicable): MAOIs are contraindicated for co-administration or within 14 days of discontinuing the MAOI.
Population-specific interaction notes (if applicable): Heightened risk of adverse outcomes in patients with renal or hepatic impairment; increased risk of respiratory depression in elderly or debilitated patients.
Interaction-related restrictions: Formal Contraindication with MAOIs; Mandatory Avoidance of alcohol; Formal Avoidance of mixed agonist/antagonist opioids.

Interaction classifications (high-level)

Classification Field Official Regulatory Documentation
Interaction severity classification (as defined in official documents): Contraindicated (MAOIs); Clinically Significant / Severe Risk (CNS Depressants, Alcohol); High Risk of Reduced Efficacy (P2Y12 Inhibitors, Mixed Opioids).
Regulatory basis (EMA / FDA / etc.): Consolidated from governmental regulatory sources, including FDA and SmPC labeling.
Interaction-context constraints (as defined in official documents): The extended-release formulation has a specific constraint regarding co-administration with alcohol due to the potential for fatal plasma concentrations.

Resulting interaction structure

Official interaction statements:

  • Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a mandatory contraindication, requiring a separation window of 14 days.
  • The co-use of alcohol or other CNS depressants is restricted due to the documented severe risk of additive pharmacodynamic effects, including profound sedation and life-threatening respiratory depression.
  • The regulatory profile acknowledges pharmacokinetic interactions where substances like Cimetidine may increase systemic exposure through inhibited metabolism, or where P-gp Inhibitors may also alter concentration levels.
  • Concomitant use with Oral P2Y12 Inhibitors may result in a documented delayed and decreased exposure to the antiplatelet agent, potentially reducing its efficacy.
  • The co-use of mixed agonist/antagonist or partial agonist opioids is formally advised against due to the risk of reduced analgesic effect or precipitated withdrawal symptoms.

Mechanism of Action

Contalgin (tramadol) is a centrally acting compound that exerts its effect through a dual pharmacodynamic mechanism, targeting key pathways in the central nervous system (CNS) to modify neurotransmission and cellular excitability.


Agonist Action at mu-Opioid Receptors

This domain involves the binding of Contalgin and its active metabolite ( O-desmethyltramadol, or M1) to mu-opioid receptors located in the brain and spinal cord. This receptor engagement initiates or suppresses inhibitory signaling sequences that modify the cellular response to incoming afferent signals, resulting in diminished cellular excitability within the nociceptive pathways.


Modulation of Monoamine Transmitters

This mechanism involves the drug's activity as a weak inhibitor of the reuptake of two crucial neurotransmitters: norepinephrine (noradrenaline) and serotonin ( 5-HT). This action elevates the concentration of these transmitters in the synaptic cleft, thereby modifying early molecular steps in the descending inhibitory pathways. The resulting physiological effect is an increase in synaptic monoamine concentration, which modulates the activity of descending pathways and alters the integration of afferent signaling.

Dosage and Administration Information

How Contalgin is Used: Official Administration Guidelines

Contalgin, an extended-release form of Morphine Sulfate, is used strictly according to guidelines for managing severe chronic pain that requires round-the-clock continuous treatment. The protocol is detailed to ensure the sustained-release mechanism functions correctly and to prevent potentially harmful rapid absorption.


Official Administration and Forms

Feature Instruction
Route of Administration Oral route only.
Available Forms Extended-release tablets and capsules (e.g., 15 mg to 200 mg strengths).

Dosing and Schedule

Contalgin is administered on a fixed schedule of every 8, 12, or 24 hours, depending on the specific extended-release formulation used. It is not indicated for as-needed (PRN) use.

  • Opioid-Naïve Adults: The standard starting dose for the extended-release tablet may be 15 mg orally every 8 or 12 hours. Dosing is highly individualized.
  • Titration and Adjustment: Dosage must be adjusted cautiously and gradually, with changes assessed over several days, to find the lowest effective dose.
  • Discontinuation: The medicine must not be stopped abruptly. The dose must be tapered (gradually reduced) under medical supervision to avoid withdrawal symptoms.

Administration Requirements

  • Swallow Instructions: The extended-release tablet must be swallowed whole. It is officially forbidden to cut, chew, crush, or dissolve the tablet, as this action defeats the extended-release mechanism and can lead to the rapid release of a large, potentially unsafe amount of morphine.
  • Food: The medication can be taken with or without food.

Population Considerations

Clinical recommendations suggest caution for specific groups. For older adults (geriatric patients), a reduction in dosage may be advisable. Dosing should also be carefully individualized in patients with renal or hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies

The following sections strictly describe the focus and findings of specific research. This information is provided for context and is not medical advice, nor should it be interpreted as promising any specific outcome or suitability for treatment.


General Research Focus on Compound X

Research has broadly explored whether Compound X (the active ingredient in Contalgin) is associated with changes in symptoms related to chronic inflammatory conditions.

  • Studies have explored the potential for reducing pain in patients with Condition A.
  • Research has been conducted to investigate biological changes associated with the compound.
  • Research has examined whether it may influence joint function in subjects with Condition B.

Key Study Findings

Study ID-456 was a multi-site trial that examined the compound.

Pain and Symptom Management

Study ID-456 included the assessment of changes in patient-reported pain scores over 12 weeks. Studies have explored the onset of potential effect in the first four weeks of administration. The research evaluated subject groups under varying administration schedules.

Long-Term Observational Data

A separate, long-term observational study (Study ID-789) collected data over two years:

  • Research has compared outcomes with traditional treatments, such as standard NSAIDs, focusing only on reported adverse events and continuation rates, not comparative efficacy.
  • Adverse event data were collected in a range of patient groups to track overall reported outcomes and discontinuation rates.

Initial Conclusions Explored

The study examined the compound as an option for subjects who did not achieve adequate response from first-line treatments. The monitoring of adverse events was included in the research protocol; however, no claims regarding the therapeutic benefit or safety for any individual should be inferred from this research summary.

Key Studies & References Clinical Guideline for the Management of Chronic Inflammatory Disorders (NICE Guideline 189 - 2024 Update)

Frequently Asked Questions (FAQ)

Common questions about Contalgin (FAQ)

Q: How quickly should I expect Contalgin to start working?

Official product information describes Contalgin as an extended-release formulation, designed to release its active ingredient slowly and continuously. This design provides sustained effects over the scheduled dosing period (e.g., 8, 12, or 24 hours), and it is not intended for the rapid relief of sudden pain. Studies exploring the onset of potential effect have typically focused on observations during the first four weeks of administration.

Q: Is Contalgin the same kind of medicine as (A commonly known pain reliever)?

No. Official classification identifies Contalgin as a centrally-acting opioid agonist and/or a compound with mu-opioid receptor activity. This pharmacological classification is distinct from most common over-the-counter pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs).

Q: Is Contalgin a non-steroidal anti-inflammatory drug (NSAID)?

No. According to regulatory documents, Contalgin is officially classified as an opioid agonist and/or a compound with mu-opioid receptor activity. This places it in a different pharmacological class than non-steroidal anti-inflammatory drugs (NSAIDs).

Q: How is the action of Contalgin different from a muscle relaxer?

The mechanism of Contalgin involves acting on pain pathways in the central nervous system (CNS), specifically through mu-opioid receptor agonism and the modulation of monoamine transmitters. This action is distinct from muscle relaxers, which typically work by targeting skeletal muscle motor control centers.

Q: Is Contalgin considered a controlled substance?

Yes, Contalgin is classified by government regulatory bodies as a controlled substance (e.g., Schedule II or IV in the U.S.). This classification is due to the drug’s potential for abuse and physical dependence.

Q: Is Contalgin a medication that is known to be addictive?

Regulatory documents describe that Contalgin, as an opioid, carries risks of addiction, abuse, and misuse. Because of the risk of developing physical dependence, the official label requires the medicine to be tapered (gradually reduced) when discontinuing use.

Q: Do the effects of Contalgin change over time?

Official information emphasizes the continuous assessment and cautious dosage adjustment that may be required during long-term treatment. This is due to the potential for patients to develop tolerance to the analgesic effect over the course of therapy.

Q: Why is Contalgin often prescribed for different conditions?

The compound is officially indicated for managing severe chronic pain. Since it exerts its effect centrally by modifying pain signals in the brain and spinal cord, it can be used for severe chronic pain stemming from various underlying medical conditions.

Q: Is Contalgin effective for nerve-related discomfort?

The official indication for Contalgin is managing severe chronic pain. While the drug's mechanism involves pathways (neuronal excitability and central pain modulation) that are relevant to nerve-related pain, the official label does not specifically name 'neuropathic pain' as an indication.

Q: How does Contalgin interact with supplements like St. John's Wort?

Official documentation warns about interactions with products that act as strong P-gp inducers and Serotonergic agents. These types of supplements may affect the drug concentration in the body or increase the risk of adverse reactions.

Q: What should I do if Contalgin doesn't seem to be working after the first few days?

Regulatory guidelines emphasize that dosage adjustments should be assessed cautiously over several days and only after the fixed schedule has been consistently followed. The medicine is not intended for as-needed use, and patients are typically advised to follow the established titration schedule as prescribed.

Q: What are the most commonly reported side effects listed in official documents for Contalgin?

Official regulatory labels include a table listing common adverse events. These frequently reported side effects typically include symptoms such as constipation, nausea, vomiting, dizziness, drowsiness, and headache.

Q: What are the signs that Contalgin might be having an unwanted effect?

Official warnings describe potential signs of serious adverse reactions, which include respiratory depression (slowed or shallow breathing) and profound sedation. Warnings also cover signs related to conditions like Serotonin Syndrome or adrenal insufficiency.

Q: Does Contalgin affect the ability to concentrate or drive?

Official warnings state that Contalgin can cause sedation and decreased levels of consciousness. Due to these effects, the ability to drive or operate machinery may be impaired, and caution is required.

Q: Does Contalgin change blood pressure?

Official labels typically list potential cardiovascular effects. These can include the risk of orthostatic hypotension, which is a drop in blood pressure that occurs when an individual stands up.

Q: What patient groups are officially excluded from using Contalgin?

Official labels include formal contraindications (absolute exclusions). These typically include patients with significant respiratory depression, severe bronchial asthma in an unmonitored setting, known hypersensitivity (severe allergy) to the compound, or those concurrently taking MAOIs (or within 14 days).

Q: Is it possible to be allergic to Contalgin?

Yes. Official regulatory labels include hypersensitivity as a potential contraindication. This means the drug is contraindicated for use in patients with a known severe allergic reaction to the active ingredient or other components.

Q: Why is Contalgin not recommended for children?

Official labels typically state that the safety and effectiveness of the extended-release formulation in pediatric patients (children) have not been established. Therefore, the product is generally not indicated for use in this population.

Q: Can Contalgin be taken during pregnancy or while breastfeeding?

Official documents describe the potential risk of Neonatal Opioid Withdrawal Syndrome in newborns if used long-term during pregnancy. Warnings also note that the drug and its metabolite are excreted into breast milk, which may carry a risk of adverse effects in the nursing infant.

Q: Can I use Contalgin if I have an existing mental health condition?

Warnings may cover potential CNS effects, such as changes in mood or anxiety. There is a specific risk of Serotonin Syndrome when Contalgin is combined with other serotonergic medicines, which include some treatments for mental health conditions.

Q: Is Contalgin affected by consumption of grapefruit?

The regulatory label warns about interactions with products that inhibit the CYP3A4 enzyme. Grapefruit is commonly known to be an inhibitor of this enzyme, and regulatory warnings advise caution when combining Contalgin with inhibitors of the CYP3A4 enzyme.

Q: What is the purpose of the coating on the Contalgin tablet?

The coating is described as a functional part of the tablet. Its purpose is to facilitate the extended-release mechanism, ensuring the active ingredient is released slowly and continuously over the intended dosing period (e.g., 8, 12, or 24 hours).

Q: Why must Contalgin be stored at room temperature?

Official storage conditions specify that the product should be stored at controlled room temperature. This requirement is intended to help maintain the integrity of the extended-release mechanism and prevent degradation of the medication.

How should Contalgin be stored and disposed of?

Contalgin (Morphine Sulfate Extended-Release) must be stored and disposed of according to strict regulatory guidelines to maintain its stability and prevent accidental harm.

Storage Conditions

Contalgin should be stored at Controlled Room Temperature, typically 20 C to 25 C. The medication must be kept in its original container and be tightly closed to protect it from moisture and heat. Do not refrigerate or freeze the product. Due to the high risk of fatal accidental exposure, the medicine must be stored in a secure, locked place and kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Contalgin should be immediately taken to a drug take-back location. If a take-back option is unavailable, the FDA advises to immediately flush the remaining tablets or capsules down the toilet, as the risk of accidental ingestion of this potent opioid outweighs the potential environmental risk.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Contalgin found in:

A-Z Index: